KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2024 ,inter alia, to consider and approve financial results for the quarter and year ended 31st March, 2024

pdf

Kilitch Drugs(I) Ltd.

18 May 2024

365.05

-0.52%

Corp. Note

KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Reg. 39 (3) - Details of Loss of Certificate …

BSE India

We hereby inform that the company has received intimation regarding loss of share certificate by Narayan Shet N Verekar

pdf

Kilitch Drugs(I) Ltd.

18 May 2024

365.05

-0.52%

Corp. Note

KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Reg. 39 (3) - Details of Loss of Certificate …

BSE India

We hereby inform you that the Company has issued duplicate share certificate to Mr. Manubhai Shah

pdf

Kilitch Drugs(I) Ltd.

14 May 2024

365.05

-0.52%

Company Update

KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Reg.24(A)-Annual Secretarial Compliance

BSE India

Please find enclosed herewith the annual secretarial compliance report for the financial year ended 31st March, 2024

pdf

Kilitch Drugs(I) Ltd.

03 May 2024

365.05

-0.52%

Corp. Note

KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Reg. 39 (3) - Details of Loss of Certificate …

BSE India

Intimation to stock exchange regarding loss of share certificate by the shareholders

pdf

Kilitch Drugs(I) Ltd.

03 May 2024

365.05

-0.52%

Corp. Note

KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Reg. 39 (3) - Details of Loss of Certificate …

BSE India

Intimation to stock exchanges regarding issuance of duplicate share certificate

pdf

Kilitch Drugs(I) Ltd.

29 Apr 2024

365.05

-0.52%

Corp. Note

KILITCH DRUGS (INDIA) LTD. - 524500 - Format of the Initial Disclosure to be made by …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyKILITCH DRUGS (INDIA) LTD. 2CIN NO.L24239MH1992PLC066718 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Pushpa Nyoupane Designation: Company Secretary and Compliance Officer EmailId: pushpanyoupane@kilitch.com Name of the Chief Financial Officer: Sunil Jain Designation: Chief Financial Officer EmailId: suniljain@kilitch.com Date: 29/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Is Kilitch Drugs(I) Ltd. worth buying?

46 Votes:

Buy 86.96%

Sell 10.87%

Hold 2.17%